The purpose of this study was to evaluate the efficacy of afatinib in EGFR-mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib.
Introduction
Epidermal growth factor receptor (EGFR)-activating mutations, mainly represented by deletion in exon 19 or the L858R substitution in exon 21, identified a distinct subgroup of non-small-cell lung cancer (NSCLC) with different prognosis and sensitivity to anti-tumor strategies.
1, 2 and 3 Eight large randomized studies have clearly demonstrated the superiority of EGFR tyrosine kinase inhibitors (TKIs) in terms of response rate (RR), progression free-survival (PFS) and tolerability compared with conventional first-line platinum-doublet chemotherapy. 4, 5, 6, 7, 8, 9, 10 and 11 Although no formal advantage in overall survival (OS) has emerged from the aforementioned studies, in all trials median survival was up to 2 to 3 years, indicating that EGFR-TKIs have changed natural history of EGFR-mutated NSCLC. Nevertheless, despite an initial dramatic tumor regression, after a median time of 9 to 12 months, all patients have disease progression due to the occurrence of resistance and the possibility of further control tumor growth inevitably decreases.
From a practical point of view, the widespread use of EGFR-TKIs as first-line therapy translates to an undoubted clinical benefit for EGFR-mutant patients, but it also leads to the emergence of a novel clinical entity. Indeed, EGFRmutant patients with acquired resistance to EGFR TKIs represent a subgroup of individuals for whom approved treatment options are only modestly active and for whom there is an urgent need for novel targeted agents. So far, several mechanisms have been recognized as responsible for acquired resistance, with the secondary T790M mutation-a characteristic point mutation in the exon 20 of the EGFR gene-representing the most prominent, being detectable in more than 50% of patients exposed to gefitinib or erlotinib. 12, 13 and 14 Afatinib (Giotrif) is an irreversible HER-family inhibitor and preclinical experience has demonstrated its activity in cell lines harboring EGFR mutations, including the T790M, thus suggesting a potential role in overcoming acquired resistance. 15 and 16 In 2 trials, the LUX-Lung 1 and LUX-Lung 4, 17 and 18 the role of afatinib was investigated at the daily dose of 50 mg in NSCLC patients resistant to EGFR TKIs defined according to the Jackman criteria, 19 demonstrating similar results. RR ranged from 8% to 10%, with a PFS of nearly 4 months, in the whole population and in subgroup analyses. Nevertheless, in both studies there was no molecular restriction for patient selection, thus precluding the possibility to derive definitive conclusions on the role of afatinib in the EGFR-mutant and resistant population.
The aim of the present study was to investigate the efficacy of afatinib in a real-life population of pretreated EGFRmutant NSCLC patients with acquired resistance to reversible EGFR TKIs.
Materials and Methods

Patient Selection
In the present study we retrospectively analyzed the outcome of patients with EGFR-mutant advanced NSCLC treated with afatinib after failure of chemotherapy and reversible EGFR TKIs in 11 Italian institutions. Eligibility criteria included: availability of clinical information, such as demographic characteristics, presence of EGFR mutation, toxicity, and efficacy data of afatinib therapy. EGFR mutational status was assessed independently at each institution, according to the Società Italiana di Anatomia Patologica e Citopatologica Diagnostica guidelines and using direct sequencing (Sanger method), pyrosequencing, or real-time polymerase chain reaction (Therascreen EGFR29 RGQ PCR mutation kit, Qiagen, Venlo, Netherlands). 20 Afatinib was provided by Boehringer Ingelheim Inc as a compassionate use and self-administered at a 50-mg dose orally once daily continuously until disease progression, unacceptable toxicity, or patient refusal to continue. Dose reductions to 40 mg per day and then to 30 mg per day were considered on the basis of individual tolerability. Toxicities were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 every 4 weeks. In all patients, tumor assessment was performed every 2 months according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria 21 and drug resupply was subordinated to tumor reassessment. Each center received the approval of the local ethics committee for each patient included in the study. All patients provided informed consent.
Statistical Analysis
A descriptive analysis on baseline characteristics was performed on the cohort of 96 EGFR-mutant lung cancer patients. RR was computed on 86 patients evaluable for efficacy. PFS was calculated from the time of starting therapy with afatinib to date of progression or last radiological assessment, and OS was calculated from the time of starting therapy with afatinib to death or last follow-up, with 95% confidence intervals using the Kaplan-Meier method.
Differences in PFS or OS according to type of EGFR mutations, type of previous therapy, adherence to Jackman criteria, or response to afatinib therapy were evaluated using the Log rank test. The significance level for all analyses was set at P < .05. Statistical analysis was performed using SPSS version 20.
Results
Patient Characteristics
A total of 96 consecutive subjects treated with afatinib between 2011 and 2013 were included in the study. Patient demographic and baseline characteristics are listed in Table 1 . 19 Most patients were female (n = 62; 64.4%), never smokers (n = 62; 64.4%), with an Eastern Cooperative Oncology Group performance status of 0 to 1 (n = 89; 92.8%) and treated with at least 3 or more therapy lines (n = 68; 70.8%). All patients had received previous EGFR TKI treatment such as gefitinib (n = 46; 47.9%), erlotinib (n = 46; 47.9%), or both (n = 4; 4.2%), as their first (n = 27; 28.1%), A Unknown means EGFR mutation not otherwise specified.
B Only in exon 18.
Efficacy
Eighty-six patients were evaluable for response according to RECIST criteria (Table 2) . Overall, 10 (11.6%) patients achieved confirmed response, including 1 CR and 9 PRs, and 38 (44.2%) obtained disease stabilization (SD) as their best response, with a disease control rate (CR + PR + SD) of 55.8%; furthermore, an additional 38 (44.2%) patients' disease progressed within the first 2 months of therapy. All responders had previously responded to reversible EGFR-TKIs and for 70% of them chemotherapy was the last therapy received before afatinib. No difference in RR was detected in patients fulfilling Jackman criteria versus patients not fulfilling the same criteria (5% in both groups). Table 1 2), as shown in Table 3 . Among the 22 evaluable patients who receive a repeated biopsy, overall RR was 4.5% (1 patient with PR), with SD of 45.4% and a progressive disease (PD) rate of 50%. Notably, none of the 6 individuals harboring the T790M mutation responded, and the only responder had the less common mutation in exon (20%), with diarrhea and skin toxicity as the most frequent events (10.6% and 11.6%, respectively); however, the occurrence of both types of adverse reactions was 5%. Other Grade 3 to 4 AEs included stomatitis in 1 patient and respiratory distress without clinical features of interstitial lung disease in another patient.
Overall, 29 patients (30%) required a dose reduction to 40 mg (22%) and to 30 mg (8%) because of persistent Grade 2 or 3 skin rash (24%), diarrhea (31%), or both (41%). Thirty patients (31.6%) had treatment delays because of toxicity, with only 3.2% of patients discontinuing afatinib because of unresolved AEs. 
Discussion
The present study, specifically conducted in EGFR-mutated NSCLCs with acquired resistance to erlotinib or gefitinib, showed that afatinib is effective only in a small fraction of NSCLC patients pretreated with reversible EGFR-TKIs.
Epidermal growth factor receptor-mutant NSCLC represents a growing clinical entity for which efficacious therapeutic options are still lacking. In clinical practice, rechallenge with EGFR TKIs has been considered as a reasonable choice and clinical trials are currently under way to investigate such a strategy. In addition, several studies to evaluate retreatment with reversible EGFR-TKIs 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33 or investigate the efficacy of irreversible EGFR TKIs 17 and 18 in the setting of acquired resistance to reversible inhibitors showed that there is a constant proportion of patients ranging up to 10% who continued to benefit from such an agent. 17, 18, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33 Nevertheless, it is not possible to accurately predict which patients will further belong to this small subgroup.
In our study, we reported a RR of 11%, quite similar to historical data 17, 18, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 33 ; more interestingly, we noted that in most cases, chemotherapy was the last therapy received before afatinib. Moreover, responding patients progressed later and lived longer than those who did not. Although this result seems too obvious, it reinforce the conviction that irrespective of mechanism responsible for erlotinib or gefitinib failure, reexposure to EGFR-TKIs after a break period could restore the sensitivity to driver inhibition probably because of the reexpansion of the initially sensitive clones. However, for the remaining 90% of our population, afatinib did not seem to produce any benefit, even when splitting results according to type of EGFR mutation or adherence to Jackman criteria.
From a biological point of view, acquired resistance is a more complex phenomenon than a simple radiologic progression during treatment and a molecular definition should be mandatory, to allocate the correct patient to the correct treatment. Prolonged exposure to erlotinib or gefitinib provides selective pressure for the development of tumor clones able to grow irrespective of the drug inhibition. Some of the mechanisms underlying the phenomenon of secondary resistance are so far elucidated, 12, 13, 14, 34, 35, 36 and 37 including the upregulation of the downstream signal by mesenchymal-epidermal transition amplification, EGFR amplification, phosphatidylinositol-3 kinase catalytic subunit alpha (PI3KCA) mutations, transition from epithelial to mesenchymal differentiation, and for a small percentage of resistant tumors, transformation into small-cell lung cancer. Furthermore, several studies recognized the emergence of the T790M EGFR gatekeeper mutation as most prominent, explaining approximately half of gefitinib/erlotinib treatment failures. 12, 13, 14, 36 and 37 Because of its ability to arrest tumor growth in in vitro models of EGFR mutant clones resistant to gefitinib and harboring the T790M mutation, afatinib has emerged as the good candidate to test in the clinical setting of acquired resistance with a specific focus on T790M-mediated resistance. 15, 16 and 37 The combination of afatinib and cetuximab, a monoclonal antibody against EGFR, showed promising efficacy in patients with acquired resistance to EGFR TKIs with an increased risk of toxicity. 38 Anecdotal series reported a potential efficacy of afatinib even in the presence of the T790M mutation. 39 and 40 Nevertheless, additional studies showed the lack of efficacy of the drug in patients with EGFR TKI acquired resistance. 17 and 18 The LUX-Lung 1 was a large phase III trial specifically designed to demonstrate the superiority of afatinib versus best supportive care in heavily pretreated NSCLC patients with secondary resistance to reversible EGFR TKIs. Although the study failed to meet its primary end point of OS, a modest but significant improvement in RR and PFS was observed for patients allocated in the active arm than in the placebo arm. 17 Similarly, in the LUX-Lung 4, a phase II single-arm Japanese trial, RR and PFS were 8.2% and 4.4 months, respectively. 18 Notably, in both trials there was not a molecular restriction for patient selection, even if the requirement for at least 12 weeks of previous EGFR TKI treatment was adopted as an enrichment strategy to increase the number of EGFR-mutated patients. As a consequence, archival tissues for EGFR assessment was available in a small percentage of patients, with only 6 cases (4 and 2 patients, in LUX-Lung 1 and LUX-Lung 4, respectively) carrying the T790M; in addiction, tumor samples were collected at the time of initial diagnosis rather than after erlotinib or gefitinib progression, thus precluding the possibility to postulate any hypothesis on the role of afatinib in presence of such a mutation. 17 and 18 Although repeating tumor biopsy is not often feasible in NSCLC, in our cohort, a not negligible number of patients underwent repeated biopsy and we identified secondary T790M in 33% of cases, with no evidence of tumor response.
It is interesting to note that 3 of these patients had a relative longer PFS; nevertheless, in such cases we cannot rule out a potential effect of the drug, even if the presence of T790M could be predictive for an indolent outcome. 36 These unmet expectations could be probably explained by the afatinib ability to inhibit not only the mutated EGFR but also the wild type protein, limiting the use of the optimal dose. 15 and 41 Therefore, a new potentially effective strategy consists of the use of a new class of covalent irreversible EGFR inhibitors, sparing the EGFR wild type and effective only against the mutated form, including T790M. CO-1686 and AZD6162 are new third-generation EGFR TKIs and preliminary results of 2 recently presented phase I studies showed promising activity in a resistant setting with the absence of typical class-related AEs.
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Taking into account all of these data suggested that the resistant setting is not the correct place to use afatinib.
Furthermore, as shown in 2 recently published phase III trials conducted in more than 700 patients, the best performance is obtained when afatinib is used early in the course of disease. 10 and 11 In LUX-Lung 3, the first trial to use the most fit comparator arm of cisplatin-pemetrexed, patients treated with afatinib had a 42% relative reduction in risk of progression compared with those who received standard chemotherapy. 10 Again, treatment with the EGFR TKI was also associated with greater RR and a better toxicity profile than chemotherapy, although Grade 3 diarrhea and skin rash occurred in 14% and 16% of cases receiving the experimental drug, respectively. The second trial, the LUX-Lung 6, in which afatinib was compared with standard doublet of cisplatin-gemcitabine in an Asian population, replicated these findings. Treatment with afatinib doubled PFS, tripled RR, and it was responsible for a 35.6% of Grade 3 to 4 drug-related AEs, mainly diarrhea and skin rash.
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At this proposal, it is a general opinion that afatinib is more toxic than the first-generation TKIs, erlotinib and gefitinib.
In the metastatic setting, the preservation of quality of life still remains one of the goals of therapy, mainly in second and subsequent lines of treatment. Moreover, regarding safety profile, our findings were consistent with the well known toxicity profile of afatinib. 10, 11, 17 and 18 In our series we reported an overall incidence of any grade AEs of 81%, quite similar to those described in all afatinib trials. 10, 11, 17 and 18 Furthermore, Grade 3 to 4 AEs, mainly diarrhea and skin rash, occurred in 20% of subjects. This percentage was not unexpected, probably because we used as a starting dose 50 mg, instead of the recommended 40 mg dose. 10 and 11 Nevertheless, only 3% of patients discontinued afatinib because of unresolved toxicity, thus suggesting that, with appropriate dose reduction and adequate supportive care, afatinib was manageable also in a cohort of heavily pretreated patients.
Conclusion
Our results showed that afatinib has only modest efficacy in a real-life population of EGFR-mutant NSCLCs with acquired resistance to erlotinib or gefitinib and its use in EGFR-mutant patients should be reserved for EGFR TKI naive individuals. Third-generation irreversible EGFR TKIs seem to offer important advantages over older compounds, especially in the management of resistant tumors, and confirmatory trials are urgently awaited.
Clinical Practice Points
•In EGFR-mutant NSCLC patients, 8 randomized studies have clearly demonstrated the superiority of EGFR-TKIs in terms of outcome and tolerability compared with standard first-line platinum-doublet chemotherapy.
•Currently, the approved treatment options in EGFR-mutant patients with acquired resistance to first-generation EGFR TKIs are only modestly active and there is an urgent need for novel targeted agents.
•Afatinib is a second-generation irreversible HER-family inhibitor and preclinical models suggest a potential role in overcoming acquired resistance, including secondary T790M mutation.
•In patients with acquired resistance to EGFR TKIs, no study has been specifically focused on individuals with EGFR mutations, precluding the possibility to derive definitive conclusions on the role of this drug in resistant cases.
•In our study, we retrospectively evaluated the outcome of 96 EGFR mutant NSCLC patients treated with afatinib after failure of chemotherapy and EGFR TKI treatments. Our data showed that afatinib was effective only in a small fraction of NSCLC patients with acquired resistance to EGFR TKIs.
•Afatinib treatment should be reserved only for EGFR-TKI-naive EGFR-mutant NSCLC patients. Abbreviations: CT = chemotherapy; EGFR = epidermal growth factor receptor; OS = overall survival; PFS = progressionfree survival; TKI = tyrosine kinase inhibitor.
Disclosure
